Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
48 hedge funds and large institutions have $105M invested in Ibere Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 47 → 48 (+1)
5% more capital invested
Capital invested by funds: $99.8M → $105M (+$4.81M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kryger Capital
London,
United Kingdom
|
+$4.11M |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$3.41M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.12M |
| 4 |
CCM
Context Capital Management
Lajolla,
California
|
+$1.12M |
| 5 |
SCM
Saba Capital Management
New York
|
+$779K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$2.25M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$1.94M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.62M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.31M |
| 5 |
HIH
HRS Investment Holdings
New York
|
-$1.09M |
IBER Hedge Fund Activity: Q1 2022 in Review
48 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q1 2022, worth a combined $105M — up 4.8% from $99.8M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IBER positions and 6 closed out — a net gain of 1 holder — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Kryger Capital, opening a new position worth an estimated $4.11M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.25M.
- 48 institutional investors held Ibere Pharmaceuticals (IBER) as of Q1 2022, up from 47 in Q4 2021.
- Funds reported $105M of Ibere Pharmaceuticals stock for Q1 2022, up 4.8% quarter-over-quarter.
- 7 funds opened new Ibere Pharmaceuticals positions in Q1 2022 and 6 closed out, a net change of +1 holder.
- The largest Ibere Pharmaceuticals buyer in Q1 2022 was Kryger Capital, an estimated $4.11M added.
- The largest Ibere Pharmaceuticals seller in Q1 2022 was D.E. Shaw & Co, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2022.